CAS: 51110-01-1; 22-((1H-Indol-3-yl)Methyl)-31-(2-Amino-2-Oxoethyl)-19,34-Bis(4-Aminobutyl)-37-(2-(2-Aminopropanamido)Acetamido)-13,25,28-Tribenzyl-10,16-Bis(1-Hydroxyethyl)-7-(Hydroxymethyl)-6,9,12,15,18,21,24,27,30,33,36-Undecaoxo-1,2-Dithia-5,8,11,14,17,20,23,26,29,32,35-Undecaazacyclooctatriacontane-4-Carboxylic Acid

专利信息

专利号:US-2024287128-A1
优先权日:2020-11-17
标题:Extremely fast solid phase synthesis
发明人：GILON CHAIM; HUREVICH MATTAN; BENTOLILA MOSHE; ALSHANSKI ISRAEL; NAOUM JOHNNY
权利人:YISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTD
摘要:The present disclosure generally relates to the field of solid phase synthesis and methods for synthesizing peptides and employing solid phase synthesis.

专利号:US-6117974-A
优先权日:1991-10-02
标题:Libraries of backbone-cyclized peptidomimetics
发明人：GILON CHAIM; HORNIK VERED
权利人:PEPTOR LTD; YISSUM RES DEV CO
摘要:Libraries of novel backbone-cyclized peptide analogs are formed by means of bridging groups attached via the alpha nitrogens of amino acid derivatives to provide novel non-peptidic linkages. Novel building units used in the synthesis of these backbone-cyclized peptide analogs are N(((-functionalized) amino acids constructed to include a spacer and a terminal functional group. One or more of these N(((-functionalized) amino acids are incorporated into a library of peptide sequences, preferably during solid phase peptide synthesis. The reactive terminal functional groups are protected by specific protecting groups that can be selectively removed to effect either backbone-to-backbone or backbone-to-side chain cyclizations. The invention is exemplified by libraries of backbone-cyclized bradykinin analogs, somatostatin analogs, BPI analogs and Substance P analogs having biological activity. Further embodiments of the invention are Interleukin-6 receptor derived peptides having ring structures involving backbone cyclization.

专利号:US-4000259-A
优先权日:1975-06-16
标 题:Cyclic dodecapeptide analogs of somatostatin and intermediates
发明人：GARSKY VICTOR M
权利人:AMERICAN HOME PROD
摘要:Cyclic dodecapeptide analogs of somatostatin without cysteine amino acid residues and intermediates obtained in the synthesis of such compounds are described. These cyclic dodecapeptides inhibit the secretion of glucagon and hence have application in the treatment of diabetes mellitus.

专利号:US-4011182-A
优先权日:1975-03-21
标 题:Cyclic undecapeptide analogs of somatostatin and intermediates
发明人：SARANTAKIS DIMITRIOS
权利人:AMERICAN HOME PROD
摘要:Cyclic undecapeptide analogs of somatostatin without cysteine amino acid residues and intermediates obtained in the synthesis of such compounds are described. These cyclic undecapeptides inhibit the secretion of the hormone somatotropin (growth hormone) without materially affecting glucagon levels.

专利号:US-2014228303-A1
优先权日:2011-06-13
标题 :Novel sglt inhibitors
发明人：JAIN RAJESH; TREHAN SANJAY; DAS JAGATTARAN; NANDA GURMEET KAUR; THUNGATHURTHI SASTRY V R S; SINGH NISHAN; SHARMA SUDHIR KUMAR
权利人:JAIN RAJESH; TREHAN SANJAY; DAS JAGATTARAN; NANDA GURMEET KAUR; THUNGATHURTHI SASTRY V R S; SINGH NISHAN; SHARMA SUDHIR KUMAR; PANACEA BIOTEC LTD
摘要:The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising novel compounds of Formula I and methods of treating or preventing one or more conditions or diseases that may be regulated or normalized via inhibition of Sodium Glucose Cotransporter-2 (SGLT-2).

专利号:US-4199500-A
优先权日:1978-11-20
标 题:Peptides related to somatostatin
发明人：SHIELDS JAMES E
权利人:LILLY CO ELI
摘要:The tetradecapaptides of the formula wherein X is H-Ala-D-Ala, H-D-Ala-Gly, or H-D-Val-Gly, or the non-toxic, pharmaceutically acceptable acid addition salts thereof; inhibit the secretion of growth hormone, while not materially inhibiting the secretion of insulin or glucagon. Intermediates used in the synthesis of the tetradecapeptides are also described.